Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ISAL 2019 | European LeukemiaNet 2017 AML recommendations: impact on risk stratification and survival

Klaus Metzeler • 1 Mar 2019
ISAL 2019
Acute Myeloid Leukemia Leukemia

Klaus Metzeler, MD, of LMU Hospital Munich, Munich, Germany, discusses what changes came about from the 2017 European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults. This interview was recorded at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.

More from Klaus Metzeler

A study investigating long-term survivorship outcomes in AML 3:30
A study investigating long-term survivorship outcomes in AML
Eva Telzerow et al. • 17 Mar 2025
The challenges with accurately diagnosing and risk-stratifying patients with MDS 4:25
The challenges with accurately diagnosing and risk-stratifying patients with MDS
Klaus Metzeler • 16 Apr 2024
The role of NGS in MDS diagnosis 3:10
The role of NGS in MDS diagnosis
Klaus Metzeler • 16 Apr 2024
Pre-MDS states: novel therapeutic approaches, and determining appropriate trial endpoints 3:17
Pre-MDS states: novel therapeutic approaches, and determining appropriate trial endpoints
Klaus Metzeler • 5 May 2023

Related Videos

The value and mission of the International Workshop on Acute Leukemias 14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddock et al. • 21 Oct 2025
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years? 1:30
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years?
Koichi Takahashi • 26 Sep 2025
One big question with Naval Daver: what AML advance could transform frontline care in three years? 1:05
One big question with Naval Daver: what AML advance could transform frontline care in three years?
Naval Daver • 26 Sep 2025
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years? 3:13
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years?
Charles Craddock • 26 Sep 2025
The content of VJHemOnc is intended for healthcare professionals